Last reviewed · How we verify
NCT03546569: CISMO
Tumor Cells, Tumor DNA and Immunological Response in Colonic Stent Placement
trial in Cancer of Colon in 20 participants. Completed in 1 February 2021.
1 January 2020
Quick facts
| Lead sponsor | Zealand University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 May 2018 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 February 2021 |
| Sites | 1 location across Denmark |
Conditions studied
- Cancer of Colon — all drugs for Cancer of Colon →
Sponsor
Zealand University Hospital
Who can join
Adults 18 to 95, any sex, with Cancer of Colon. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate levels of circulating cell free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTC) and immunological changes after self-expanding metal stent (SEMS) placement for malignant obstruction in the colon, and interpret these levels in relation to overall- and disease-free survival. Furthermore, we intend to study the opportunity to identify patients with a higher risk of recurrence due to the SEMS placement by monitoring cfDNA and ctDNA-levels, as it may be a potential biomarker to initiate or optimize chemotherapy and thereby ensure a better prognosis for the patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Liquid biopsies for colorectal cancer: a narrative review of ongoing clinical trials and the current use of this technology at a comprehensive cancer center.
Broccard SP, Kasbi AA, Bagaria SP, Jones J, et al · · 2022 · cited 8× · PMID 35284120 · DOI 10.21037/jgo-21-470
Verify or expand the search:
- PubMed search for NCT03546569
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cancer of Colon
Currently open trials in the same condition.
- NCT05163028 — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations · Phase 1 · active not recruiting
- NCT05179824 — Tempus Priority Study: A Pan-tumor Observational Study · active not recruiting
- NCT04259398 — Anesthesia and Cancer Study: Colon Cancer · NA · active not recruiting
Other Zealand University Hospital trials
Trials by the same sponsor.
- NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
- NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
- NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
- NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
- NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03546569 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
- Last refreshed: 25 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03546569.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing